TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension

Cardiovascular Research

Volumn 98, Issue 3, 2013, Pages 360-371

  Basu, Ratnadeep ^a   Lee, Jiwon ^a   Morton, Jude S ^a   Takawale, Abhijit ^a   Fan, Dong ^a   Kandalam, Vijay ^a   Wang, Xiuhua ^a   Davidge, Sandra T ^a   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Extracellular matrix; Hypertension; Tissue inhibitor of metalloproteinase; Vascular remodelling

Indexed keywords

ANGIOTENSIN II; COLLAGEN; DOXYCYCLINE; ELASTASE; ELASTIN; GELATINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CAROTID ARTERY; CONTROLLED STUDY; EX VIVO STUDY; HYPERTENSION; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR REMODELING;

EXTRACELLULAR MATRIX; HYPERTENSION; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULAR REMODELLING;

ANGIOTENSIN II; ANIMALS; ARTERIAL PRESSURE; CAROTID ARTERIES; COLLAGEN; DISEASE MODELS, ANIMAL; ELASTIN; GELATINASES; HYPERTENSION; MATRIX METALLOPROTEINASE INHIBITORS; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; VASOCONSTRICTION; VASODILATION;

EID: 84878000928     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt067     Document Type: Article

References (54)

1. Cummins PM, von Offenberg Sweeney N, Killeen MT, Birney YA, Redmond EM, Cahill PA. Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with. Am J Physiol Heart Circ Physiol 2007; 292:H28-H42.
2. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev 2009;89:957-989.
3. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269: 9352-9360.
4. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulfated glycosami-noglycans of the extracellular matrix. J Biol Chem 2000;275:31226-31232.
5. Armstrong C, Abilleira S, Sitzer M, Markus HS, Bevan S. Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke 2007;38: 2895-2899.
6. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007;50:212-218.
7. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and Janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 2010;56:879-884.
8. Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 2009;20:1223-1235.
9. Johnson AW, Kinzenbaw DA, Modrick ML, Faraci FM. Small-molecule inhibitors of signal transducer and activator of transcription 3 protect against angiotensin II-induced vascular dysfunction and hypertension. Hypertension 2013;61:437-442.
10. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 2011;57:314-322.
11. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002;35:923-929.
12. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M. Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci USA 2001;98:7469-7474.
13. Morton JS, Rueda-Clausen CF, Davidge ST. Flow-mediated vasodilation is impaired in adult rat offspring exposed to prenatal hypoxia. J Appl Physiol 2011;110:1073-1082.
14. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 2010;106: 796-808.
15. Kassiri Z, Defamie V, Hariri M, Oudit GY, Anthwal S, Dawood F et al. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in TIMP3-deficient heart. J Biol Chem 2009;284:29893-29904.
16. Chow MJ, Zhang Y. Changes in the mechanical and biochemical properties of aortic tissue due to cold storage. J Surg Res 2010;171:434-442.
17. Ju H, Dixon IM. Extracellular matrix and cardiovascular diseases. Can J Cardiol 1996;12: 1259-1267.
18. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005;97:380-390.
19. Kandalam V, Basu R, Abraham T, Wang X, Awad A, Wang W et al. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol 2010;299:H1012-H1023.
20. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012;103:209-279.
21. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360.
22. Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008;117:905-914.
23. Humphrey JD. Mechanisms of arterial remodeling in hypertension: coupled roles of wall shear and intramural stress. Hypertension 2008;52:195-200.
24. Laurent S, Tropeano AI, Lillo-Lelouet A, Jondeau G, Laloux B, Boutouyrie P. Local pulse pressure is a major determinant of large artery remodelling. Clin Exp Pharmacol Physiol 2001;28:1011-1014.
25. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000;36:312-318.
26. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29:290-308.
27. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274: 21491-21494.
28. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO syn-thase inhibition. Hypertension 2005;45:432-437.
29. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM et al. Ler-canidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008;591:224-230.
30. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198: 320-331.
31. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
32. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
33. Castoldi G, Di Gioia CR, Pieruzzi F, D'Orlando C, Van De Greef WM, Busca G et al. ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo. Am J Physiol Heart Circ Physiol 2003;284:H635-H643.
34. Castoldi G, di Gioia CR, Travaglini C, Busca G, Redaelli S, Bombardi C et al. Angio-tensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: evidence of a pressure-independent effect. Clin Exp Pharmacol Physiol 2007;34:205-209.
35. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2007;292:H2438-H2448.
36. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S et al. Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006;13:227-231.
37. Basu R, Fan D, Kandalam V, Lee J, Das SK, Wang X et al. Loss of TIMP3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II. J Biol Chem 2012; 287:44083-44096.
38. Schluter KD, Wenzel S. Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacol Ther 2008;119:311-325.
39. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010;106: 1675-1680.
40. 2+-calmodulin protein kinase II and promotes a death pathway conserved across different species. Circ Res 2009;105:1204-1212.
41. Palomeque J, Delbridge L, Petroff MV. Angiotensin II: a regulator of cardiomyocyte function and survival. Front Biosci 2009;14:5118-5133.
42. Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2012;17:693-706.
43. Huo Y, Cheng Y, Zhao X, Lu X, Kassab GS. Biaxial vasoactivity of porcine coronary artery. Am J Physiol Heart Circ Physiol 2012;302:H2058-H2063.
44. Khamdaeng T, Luo J, Vappou J, Terdtoon P, Konofagou EE. Arterial stiffness identification of the human carotid artery using the stress-strain relationship in vivo. Ultrasonics 2012;52:402-411.
45. Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, Kaplan BS et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 2006;114:I365-I370.
46. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006;176:721-725.
47. English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, Soloway PD et al. Individual TIMP deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 2006; 281:10337-10346.
48. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4and 1/4-length fragments. J Biol Chem 1995;270:5872-5876.
49. Shipley JM, Doyle GA, Fliszar CJ, Ye QZ, Johnson LL, Shapiro SD et al. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem 1996;271:4335-4341.
50. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994;269:6632-6636.
51. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2011;301:H87-H97.
52. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011;64:567-572.
53. Fujita H, Sakamoto N, Ishimatsu Y, Kakugawa T, Hara S, Hara A et al. Effects of doxy-cycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis. Respiration 2011;81:420-430.
54. Ennis T, Jin J, Bartlett S, Arif B, Grapperhaus K, Curci JA. Effect of novel limited-spectrum MMP inhibitor XL784 in abdominal aortic aneurysms. J Cardiovasc Pharmacol Ther 2012;17:417-426.